ELUT
Elutia Inc.
$0.96
+0.05 (+5.25%)
At close · Jul 15
Market Cap
$42.00M
Shares
44,208,236
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.96
Open$0.92
Day$0.92–0.96
52W$0.50–2.50
Avg vol 30d69K
Short int53K · 0.1% float · 1.0d
Short vol6%
Last earningsMay 14, 2026
DataOct 2020–Jul 2026
Filing10-Q · May 15
Up next
Next earnings call
Aug 13, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 15, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.7 · calm
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+2%
above
Price vs 50-day avg
−6%
below
RSI (14)
48
neutral
MACD trend
Positive
52-week position
23%
mid-range
Momentum
relative strength
1-month return
−1%
trailing
6-month return
+4%
trailing
YTD return
+39%
this year
Relative strength
−6%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow
Distributing
2 of 35 funds reported for Jun 30 · net -19.5K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.12% of float · ▲ +106.2% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
35 holders — near 3-yr high, broad support
Squeeze score
41
elevated · 0–100
Fundamentals
Revenue growth
−15%
Y/Y
Gross margin
54%
expanding
EPS growth
+147%
Y/Y
Free cash flow
$-46.7M
Valuation
P/E 1
below peers
Balance sheet
$12.5M
net cash
Quant / Vol
risk profile
Volatility
79%
annualized · 1-yr
Max drawdown
−79%
past year
ATR
7.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 14, 2026
Gross margin
· at scale
at least 80%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+2%
Bullish
Price vs 50-day avg
−6%
Bearish
RSI (14)
48
Neutral
MACD trend
Positive
Bullish
52-week position
23%
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow
Distributing
2 of 35 funds reported for Jun 30 · net -19.5K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.12% of float · ▲ +106.2% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
35 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $1
Now $1 · 23%
52-wk high $3
vs 200-day avg +2%
vs 50-day avg -6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -$4.4M | Q1 2026 | — |
| Adjusted gross margin non-GAAP | 66.5% | Q1 2026 | — |
| Total cash and escrow funds | $36.5M | Q1 2026 | — |
| Cash balance | $36.4M | As of December 31, 2025 | — |
| Net sales of Cardiovascular products | $1.2M | Q4 2025 | — |
| Net sales of SimpliDerm | $2.1M | Q4 2025 | — |
| Pre-funded warrants outstanding | 4.5M | As of December 31, 2025 | — |
| Shares of Class A common stock outstanding | 42.8M | As of December 31, 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ELUT
this stock
Elutia Inc.
|
$42.00M | +38.5% | -15.0% | 1.0 | 0.1% |
|
ABT
Abbott Laboratories
|
$172.14B | -20.7% | +5.7% | 27.7 | 1.3% |
|
SYK
Stryker Corp
|
$126.90B | -9.7% | +11.2% | 38.3 | 1.8% |
|
MDT
Medtronic plc
|
$106.96B | -15.5% | +8.4% | 22.4 | 1.5% |
|
BSX
Boston Scientific Corp
|
$66.32B | -54.9% | +5.5% | 18.7 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ELUT | +1.0% | -0.9% | +4.3% | -2.1% | +38.5% |
| SPY | +1.3% | -0.2% | +10.1% | +1.1% | +10.7% |
| vs SPY | -0.2% | -0.8% | -5.8% | -3.1% | +27.8% |